Alkem Laboratories (NSE:ALKEM) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ALKEM Alkem Laboratories Ltd NSE:ALKEM
97 GF Score
Price ₹5,613.00
GF Value ₹6,129.56
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Alkem Laboratories Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Alkem Laboratories is: Moderate Risk: Sensitive, better choose undervalued stock.

Alkem Laboratories  (NSE:ALKEM) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Alkem Laboratories Risk Assessment Related Terms

NSE:ALKEM vs ZTS: Risk Assessment Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Alkem Laboratories's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alkem Laboratories Risk Assessment vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alkem Laboratories's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Alkem Laboratories's Risk Assessment falls into.


NSE:ALKEM
97GF Score
Alkem Laboratories Ltd NSE:ALKEM
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Alkem Laboratories (NSE:ALKEM) Overvalued in 2026?

Based on GuruFocus' analysis, Alkem Laboratories stock appears to be undervalued. The current stock price of ₹5,613.00 is trading 8.4% below its estimated GF Value™ of ₹6,129.56. GuruFocus considers Alkem Laboratories to be Fairly Valued.

Key valuation signals for NSE:ALKEM:

  • Risk Assessment:
  • GF Value™: ₹6,129.56 vs. price of ₹5,613.00 (8.4% below fair value)
  • GF Score™: 97/100 with 1 warning sign

No single metric tells the full story. See the NSE:ALKEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alkem Laboratories Business Description

Other Exchanges 539523:India
Address Senapati Bapat Marg, Alkem House, Devashish Building, Lower Parel, Mumbai, MH, IND, 400 013
Alkem Laboratories Ltd is an Indian pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals in acute and chronic therapeutic areas, such as anti-infective, pain and analgesics, vitamins/minerals/nutrients, cardiac and Diabetology, Gynecology, neuro/central nervous system, dermatology, anti-diabetes, anti-osteoporosis, cardiovascular, and muscle relaxants, which are marketed in Indian and International markets. It operates through the pharmaceutical business segment.
97GF Score

Get the complete analysis for NSE:ALKEM

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹5,613.00
Price
₹6,129.56
GF Value